Skip to main content
Top
Published in: Journal of Cachexia, Sarcopenia and Muscle 3/2013

01-09-2013 | Original Article

Development of a practical screening tool to predict low muscle mass using NHANES 1999–2004

Authors: Michael J. Goodman, Sameer R. Ghate, Panagiotis Mavros, Shuvayu Sen, Robin L. Marcus, Elizabeth Joy, Diana I. Brixner

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 3/2013

Login to get access

Abstract

Background

Skeletal muscle mass declines after the age of 50. Loss of skeletal muscle mass is associated with increased morbidity and mortality.

Objective

This study aims to identify predictors of low skeletal muscle mass in older adults toward development of a practical clinical assessment tool for use by clinicians to identify patients requiring dual-energy X-ray absorptiometry (DXA) screening for muscle mass.

Methods

Data were drawn from the National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2004. Appendicular skeletal mass (ASM) was calculated based on DXA scans. Skeletal muscle mass index (SMI) was defined as the ratio of ASM divided by height in square centimeters. Elderly participants were classified as having low muscle mass if the SMI was 1 standard deviation (SD) below the mean SMI of young adults (20–40 years old). Logistic regression was conducted separately in males and females age ≥65 years of age to examine the relationship between patients identified as having low muscle mass and health behavior characteristics, adjusting for comorbid conditions. The model was validated on a separate sample of 200 patients.

Results

Among the NHANES study population, 551 (39.7 %) males and 374 (27.5 %) females had a SMI below the 1 SD cutoff point. NHANES study subjects with a low SMI were older (mean age, 76.2 vs. 72.7 for male; 76.0 vs. 73.7 for female; and both p < 0.0001) and had a lower body mass index (mean BMI, 24.1 vs. 29.4 for male; 22.9 vs. 29.7 for female; p < 0.0001). In adjusted logistic regression analyses, age (for males) and BMI (for both males and females) remained statistically significant. A parsimonious logistic regression model adjusting for age and BMI only had a C statistic of 0.89 for both males and females. The discriminatory power of the parsimonious model increased to 0.93 for males and 0.95 for females when the cutoff defining low SMI was set to 2 SD below the SMI of young adults. In the validation sample, the sensitivity was 81.6 % for males and 90.6 % for females. The specificity was 66.2 % for males and females.

Conclusions

BMI was strongly associated with a low SMI and may be an informative predictor in the primary care setting. The predictive model worked well in a validation sample.
Literature
1.
go back to reference Janssen I et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:80–5.PubMedCrossRef Janssen I et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:80–5.PubMedCrossRef
2.
go back to reference Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol A Biol Sci Med Sci. 1995;50 Spec No:107–12.PubMed Nair KS. Muscle protein turnover: methodological issues and the effect of aging. J Gerontol A Biol Sci Med Sci. 1995;50 Spec No:107–12.PubMed
3.
go back to reference Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003;58:M911–6.PubMedCrossRef Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003;58:M911–6.PubMedCrossRef
4.
go back to reference Zacker RJ. Health-related implications and management of sarcopenia. JAAPA. 2006;19:24–9.PubMed Zacker RJ. Health-related implications and management of sarcopenia. JAAPA. 2006;19:24–9.PubMed
5.
go back to reference Baumgartner RN et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63.PubMedCrossRef Baumgartner RN et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63.PubMedCrossRef
6.
go back to reference Melton LJ, Khosla S, Riggs BL. Epidemiology of sarcopenia. Mayo Clin Proc. 2000;75 Suppl:10–2. discussion S12-3. Melton LJ, Khosla S, Riggs BL. Epidemiology of sarcopenia. Mayo Clin Proc. 2000;75 Suppl:10–2. discussion S12-3.
7.
go back to reference Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57:M772–7.PubMedCrossRef Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57:M772–7.PubMedCrossRef
8.
go back to reference Castillo EM et al. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am J Prev Med. 2003;25:226–31.PubMedCrossRef Castillo EM et al. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am J Prev Med. 2003;25:226–31.PubMedCrossRef
9.
go back to reference Foley RN et al. Kidney function and sarcopenia in the United States general population: NHANES III. Am J Nephrol. 2007;27:279–86.PubMedCrossRef Foley RN et al. Kidney function and sarcopenia in the United States general population: NHANES III. Am J Nephrol. 2007;27:279–86.PubMedCrossRef
11.
go back to reference Heymsfield SB et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr. 1990;52:214–8.PubMed Heymsfield SB et al. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr. 1990;52:214–8.PubMed
12.
go back to reference Cesari M, Pahor M. Target population for clinical trials on sarcopenia. J Nutr Health Aging. 2008;12:470–8.PubMedCrossRef Cesari M, Pahor M. Target population for clinical trials on sarcopenia. J Nutr Health Aging. 2008;12:470–8.PubMedCrossRef
13.
go back to reference StataCorp. Stata Statistical Software: release 10. College Station, TX: StataCorp LP; 2007. StataCorp. Stata Statistical Software: release 10. College Station, TX: StataCorp LP; 2007.
14.
go back to reference Cox DR, Snell EJ. Analysis of binary data. In: Monographs on statistics and applied probability. 2nd ed. London: Chapman & Hall; 1989. vii, 236 p. Cox DR, Snell EJ. Analysis of binary data. In: Monographs on statistics and applied probability. 2nd ed. London: Chapman & Hall; 1989. vii, 236 p.
15.
go back to reference SAS Institute. SAS System for Windows, Version 9.2. Cary, NC: SAS Institute; 2009. SAS Institute. SAS System for Windows, Version 9.2. Cary, NC: SAS Institute; 2009.
16.
go back to reference Robbins J et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298:2389.PubMedCrossRef Robbins J et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298:2389.PubMedCrossRef
17.
go back to reference Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345–52.PubMedCrossRef Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009;302:2345–52.PubMedCrossRef
18.
go back to reference Wilson PW et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMedCrossRef Wilson PW et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMedCrossRef
19.
go back to reference Muscaritoli M et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics. Clin Nutr. 2010;29:154–9.PubMedCrossRef Muscaritoli M et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics. Clin Nutr. 2010;29:154–9.PubMedCrossRef
20.
go back to reference Chomentowski P et al. Moderate exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. J Gerontol A Biol Sci Med Sci. 2009;64:575–80.PubMedCrossRef Chomentowski P et al. Moderate exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. J Gerontol A Biol Sci Med Sci. 2009;64:575–80.PubMedCrossRef
21.
go back to reference Goodpaster BH et al. Effects of physical activity on strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial. J Appl Physiol. 2008;105:1498–503.PubMedCrossRef Goodpaster BH et al. Effects of physical activity on strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial. J Appl Physiol. 2008;105:1498–503.PubMedCrossRef
23.
go back to reference Plotnikoff RC et al. Factors associated with physical activity in Canadian adults with diabetes. Med Sci Sports Exerc. 2006;38:1526–34.PubMedCrossRef Plotnikoff RC et al. Factors associated with physical activity in Canadian adults with diabetes. Med Sci Sports Exerc. 2006;38:1526–34.PubMedCrossRef
24.
go back to reference Baumgartner RN et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12:1995–2004.PubMedCrossRef Baumgartner RN et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12:1995–2004.PubMedCrossRef
25.
go back to reference Davison KK et al. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc. 2002;50:1802–9.PubMedCrossRef Davison KK et al. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. J Am Geriatr Soc. 2002;50:1802–9.PubMedCrossRef
26.
go back to reference Stenholm S et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11:693–700.PubMedCrossRef Stenholm S et al. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11:693–700.PubMedCrossRef
27.
go back to reference Jarosz PA, Bellar A. Sarcopenic obesity: an emerging cause of frailty in older adults. Geriatr Nurs. 2009;30:64–70.PubMedCrossRef Jarosz PA, Bellar A. Sarcopenic obesity: an emerging cause of frailty in older adults. Geriatr Nurs. 2009;30:64–70.PubMedCrossRef
28.
go back to reference Lee RC et al. Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr. 2000;72:796–803.PubMed Lee RC et al. Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr. 2000;72:796–803.PubMed
Metadata
Title
Development of a practical screening tool to predict low muscle mass using NHANES 1999–2004
Authors
Michael J. Goodman
Sameer R. Ghate
Panagiotis Mavros
Shuvayu Sen
Robin L. Marcus
Elizabeth Joy
Diana I. Brixner
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 3/2013
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-013-0107-9

Other articles of this Issue 3/2013

Journal of Cachexia, Sarcopenia and Muscle 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine